Form 4: AtriCure Executive Vinayak Doraiswamy Reports Stock Transactions

AtriCure's Chief Scientific Officer, Vinayak Doraiswamy, reports acquisition and disposal of company stock related to restricted stock and performance share awards.

Summary

• Vinayak Doraiswamy, Chief Scientific Officer of AtriCure, Inc., filed a Form 4 detailing changes in beneficial ownership of the company's stock.
• On March 1, 2024, Doraiswamy acquired 19,294 shares of common stock through a restricted stock award and 9,328 shares through the vesting of a performance share award, both at $0 cost.
• On the same day, Doraiswamy disposed of 8,855 shares at $36.28 per share to cover tax withholding obligations related to the vesting of previous stock awards.
• Following these transactions, Doraiswamy directly owns 59,077 shares of AtriCure common stock.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing stock transactions. It doesn't inherently convey positive or negative sentiment, but rather provides factual information.

Positives

• The vesting of performance share awards suggests that the company met certain performance goals and service period requirements.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders, allowing investors to track executive compensation and ownership changes.

Stakeholder Impact

• Shareholders can monitor insider transactions to gain insights into management's perspective on the company's stock.

Key Dates